| Literature DB >> 31690561 |
Vincent A van Vugt1, Johannes C van der Wouden2, Rosie Essery3, Lucy Yardley3, Jos W R Twisk4, Henriëtte E van der Horst2, Otto R Maarsingh2.
Abstract
OBJECTIVE: To investigate the clinical effectiveness and safety of stand alone and blended internet based vestibular rehabilitation (VR) in the management of chronic vestibular syndromes in general practice.Entities:
Mesh:
Year: 2019 PMID: 31690561 PMCID: PMC6829201 DOI: 10.1136/bmj.l5922
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Baseline characteristics of participants assigned to stand alone vestibular rehabilitation (VR), blended VR, or usual care. Values are numbers (percentages) unless stated otherwise
| Characteristics | Stand alone VR (n=98) | Blended VR (n=104) | Usual care (n=120) | Total sample (n=322) |
|---|---|---|---|---|
| Mean (SD) age (years) | 66.7 (9.5) | 67.4 (9.8) | 67.0 (9.4) | 67.0 (9.5) |
| Female | 64 (65) | 69 (66) | 64 (53) | 197 (61) |
| Level of education: | ||||
| Low | 33 (34) | 37 (36) | 36 (30) | 106 (33) |
| Middle | 25 (26) | 31 (30) | 30 (25) | 86 (27) |
| High | 40 (41) | 36 (35) | 54 (45) | 130 (40) |
| Living situation: | ||||
| Alone | 34 (35) | 33 (32) | 35 (29) | 102 (32) |
| With partner | 64 (65) | 71 (68) | 85 (71) | 220 (68) |
| No of chronic diseases*: | ||||
| 0 | 59 (60) | 64 (62) | 63 (53) | 186 (58) |
| 1 | 28 (29) | 32 (31) | 41 (34) | 101 (31) |
| 2 | 8 (8) | 4 (4) | 12 (10) | 24 (7) |
| ≥3 | 3 (3) | 4 (4) | 4 (3) | 11 (3) |
| Time since vestibular diagnosis†: | ||||
| 1-6 months | 15 (15) | 22 (21) | 13 (11) | 50 (16) |
| 6 months to 2 years | 28 (29) | 27 (26) | 39 (33) | 94 (29) |
| 2-10 years | 31 (32) | 44 (42) | 48 (40) | 123 (38) |
| >10 years | 23 (24) | 11 (11) | 18 (15) | 52 (16) |
| Self reported vestibular diagnosis†: | ||||
| No known diagnosis | 67 (68) | 69 (66) | 77 (64) | 213 (66) |
| Benign paroxysmal positional vertigo | 11 (11) | 17 (16) | 22 (18) | 50 (16) |
| Meniere’s disease | 9 (9) | 9 (9) | 10 (8) | 28 (9) |
| Vestibular neuritis | 6 (6) | 4 (4) | 7 (6) | 17 (5) |
| PPPD | 0 (0) | 1 (1) | 0 (0) | 1 (0) |
| Other‡ | 4 (4) | 4 (4) | 2 (2) | 10 (3) |
| Disorders at baseline according to PHQ: | 14 (14) | 16 (15) | 23 (19) | 53 (17) |
| Panic disorder | 2 (2) | 3 (3) | 5 (4) | 10 (3) |
| Generalised anxiety disorder | 12 (12) | 15 (14) | 19 (16) | 46 (14 |
| Major depressive disorder | 5 (5) | 6 (6) | 9 (8) | 20 (6) |
PPPD=persistent postural-perceptual dizziness; PHQ=patient health questionnaire.
Chronic non-specific lung disease, cardiac disease, peripheral arterial disease, stroke, diabetes mellitus, arthritis, and cancer.
Data on this variable was missing for three participants: stand alone VR (n=1), usual care (n=2).
Traumatic brain injury, cerebrovascular accident, Parkinson’s disease, bacterial meningitis, and vestibular organ surgical procedures.
Comparison of primary outcome between treatment groups
| Primary outcome measure | Mean (SD) score | Crude mean difference (95% CI)* | Adjusted mean difference (95% CI)† | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Stand alone VR | Blended VR | Usual care | Stand alone VR | Blended VR | Stand alone VR | Blended VR | |||
| VSS-SF (intention to treat)‡: | n=98 | n=104 | n=120 | n=218 | n=224 | n=218 | n=224 | ||
| Baseline | 14.1 (8.9) | 13.8 (8.3) | 13.2 (8.6) | - | - | - | - | ||
| 3 months | 8.1 (7.4) | 8.6 (7.1) | 11.5 (9.9) | −4.2 (−5.9 to −2.5) | −3.9 (−5.5 to −2.2) | −4.3 (−5.9 to −2.6) | −3.9 (−5.5 to −2.3) | ||
| 6 months | 7.5 (7.8) | 8.7 (6.9) | 10.9 (9.3) | −4.0 (−5.8 to −2.3) | −3.5 (−5.1 to −1.8) | −4.1 (−5.8 to −2.5) | −3.5 (−5.1 to −1.9) | ||
| VSS-SF (per protocol)§: | n=47 | n=55 | n=120 | n=167 | n=175 | n=167 | n=175 | ||
| Baseline | 13.2 (6.2) | 15.0 (8.6) | 13.2 (8.6) | - | - | - | - | ||
| 3 months | 6.0 (4.0) | 10.0 (8.0) | 11.5 (9.9) | −6.0 (−8.1 to −4.0) | −3.4 (−5.3 to −1.4) | −6.0 (−8.0 to −3.9) | −3.3 (−5.2 to −1.4) | ||
| 6 months | 5.9 (5.0) | 9.4 (7.4) | 10.9 (9.3) | −5.4 (−7.5 to −3.4) | −3.6 (−5.6 to −1.7) | −5.4 (−7.4 to −3.4) | −3.5 (−5.5 to −1.6) | ||
VR=vestibular rehabilitation; VSS-SF=vertigo symptom scale-short form, range 0-60, clinically relevant difference 3 points.
Adjusted for baseline values and repeated measurements within participants.
Adjusted for baseline values, repeated measurements within participants, age, sex, level of education, living situation, number of chronic diseases, time since vestibular diagnosis, and presence of a panic disorder, generalised anxiety disorder, or major depressive disorder at baseline.
All participants analysed according to allocation.
Only participants in stand alone VR group who completed all six online sessions and participants in blended VR group who completed all six online sessions and both physiotherapist visits were analysed.
Comparison of secondary outcomes between treatment groups
| Secondary outcome measures | Treatment group | Crude mean difference (95% CI)* | Adjusted mean difference (95% CI)† | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Stand alone VR | Blended VR | Usual care | Stand alone VR | Blended VR | Stand alone VR | Blended VR | |||
|
| |||||||||
| DHI: | |||||||||
| Baseline | 34.8 (18.5) | 36.0 (21.9) | 35.8 (19.9) | - | - | - | - | ||
| 3 months | 24.4 (20.8) | 26.4 (20.6) | 29.2 (21.1) | −4.5 (−8.1 to −0.8) | −3.9 (−7.5 to −0.3) | −4.6 (−8.2 to −1.1) | −3.9 (−7.4 to −0.4) | ||
| 6 months | 21.5 (20.4) | 25.4 (21.6) | 27.6 (21.5) | −4.7 (−8.4 to −1.1) | −4.4 (−8.0 to −0.8) | −4.9 (−8.4 to −1.3) | −4.5 (−8.0 to −0.9) | ||
| GAD-7: | |||||||||
| Baseline | 3.7 (4.6) | 4.0 (4.3) | 4.5 (4.8) |
|
|
|
| ||
| 3 months | 3.1 (3.8) | 2.9 (3.4) | 4.5 (5.0) | −1.0 (−1.9 to −0.1) | −1.3 (−2.2 to −0.5) | −1.1 (−1.9 to −0.3) | −1.4 (−2.2 to −0.6) | ||
| 6 months | 2.6 (3.3) | 2.7 (3.5) | 4.2 (5.0) | −1.1 (−1.9 to −0.2) | −1.1 (−2.0 to −0.3) | −1.2 (−2.0 to −0.4) | −1.2 (−2.0 to −0.4) | ||
| PHQ-9: | |||||||||
| Baseline | 4.5 (4.7) | 5.4 (4.5) | 5.9 (5.4) |
|
|
|
| ||
| 3 months | 4.2 (4.2) | 4.3 (4.2) | 5.3 (5.0) | −0.3 (−1.3 to 0.6) | −0.9 (−1.8 to 0.0) | −0.5 (−1.4 to 0.4) | −0.9 (−1.8 to 0.0) | ||
| 6 months | 3.5 (4.3) | 4.0 (3.7) | 4.9 (5.1) | −0.5 (−1.4 to 0.5) | −0.8 (−1.7 to 0.2) | −0.6 (−1.5 to 0.3) | −0.8 (−1.7 to 0.1) | ||
|
| |||||||||
| Subjective improvement: | |||||||||
| 3 months | 49/91 (54) | 54/97 (56) | 39/107 (36) | 2.1 (1.2 to 3.6)*‡§ | 2.2 (1.2 to 3.8)*‡§ | 2.2 (1.2 to 4.1) | 2.1 (1.2 to 3.8) | ||
| 6 months | 46/87 (53) | 48/93 (52) | 43/110 (39) | ||||||
VR=vestibular rehabilitation; DHI=dizziness handicap inventory, range 0-100; GAD-7= generalised anxiety disorder assessment (GAD)-7 subscale, a measure for severity of anxiety symptoms, range 0-21; PHQ-9=patient health questionnaire-9, a measure for severity of depressive symptoms, range 0-27; subjective improvement = dichotomous evaluation of vestibular symptoms compared to baseline measurement: improved or not improved (ie, worse or the same).
All analyses reported in table were performed on an intention-to-treat basis, with participants analysed according to allocation.
Adjusted for baseline values and repeated measurements within participants.
Adjusted for baseline values, repeated measurements within participants, age, sex, level of education, living situation, number of chronic disease, time since vestibular diagnosis, and presence of a panic disorder, generalised anxiety disorder, or major depressive disorder at baseline.
Comparison of overall effect over six months follow-up.
Odds ratios (95% CI).
Adjusted odds ratios (95% CI).